Analyst Consensus ?
ConsensusBuy31 ratings
Bullish1858.1%
Neutral1238.7%
Bearish13.2%
Ventas, Inc. · VTR · FY2025 Q2 · Calendar Q3 2025
Ventas raises guidance as senior housing drives Q2 growth
The current analysis supports a constructive operating thesis for Ventas: senior-housing demand, constrained supply, acquisitions and SHOP conversions are supporting growth. The main test is whether occupancy and pricing gains, investment returns and policy-sensitive businesses remain durable.
Reported After market closeNYSEReal Estate
$39.89B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$0.87
Consensus $0.85
EPS surprise
+2.4%
Reported versus consensus
Reported revenue
$1.42B
Consensus $1.40B
Revenue surprise
+1.1%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+1.1%
Event window
SPY move
-0.4%
Same window
Abnormal move
+1.4%
Stock minus SPY
Volume
1.8×
Versus trailing sessions
Subsequent drift
+0.5%
Up to 20 sessions
VTRSPY benchmark
Ask FN2 about VTR FY2025 Q2
Transcript, numbers and history already loaded
Why did VTR rise 1.1% after beating EPS estimates in FY2025 Q2?What changed in VTR's guidance and outlook in FY2025 Q2?Give me the bull and bear case for VTR after FY2025 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
Compared with the prior-quarter analysis, management raised guidance, expanded the senior-housing investment target to $2 billion, and reported continued acquisition and conversion activity. The current analysis also highlighted outpatient medical policy developments and research-portfolio pressure as areas to monitor.
Guidance delta
Management raised full-year 2025 FFO guidance to $3.44 per share and increased senior-housing investment guidance to $2 billion.
Key takeaways
- Q2 normalized FFO increased 9% year over year and same-store cash NOI rose 7%.
- SHOP NOI growth was 18%, supported by occupancy, pricing and operator transitions.
- Management described a $2 billion senior-housing investment pipeline, with $1.1 billion closed year to date.
Management priorities
- Continue converting triple-net communities to SHOP.
- Deploy the senior-housing investment pipeline while targeting low-to-mid-teens unlevered IRRs.
- Use portfolio refresh capital expenditure and operator relationships to improve performance.
Follow VTR with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$82.04Current
$51Low
$83.31Average
$110High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Oct 11, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Sep 21, 2026 |
| Scotiabank | Sector Perform | Sector Perform | Maintain | Sep 2, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Sep 1, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Aug 31, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Aug 14, 2026 |
| BMO Capital | Outperform | Outperform | Maintain | Aug 11, 2026 |
| Citigroup | Buy | Buy | Maintain | Aug 4, 2026 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 22, 2026 |
| Jefferies | Buy | Buy | Maintain | May 13, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | May 11, 2026 |
| Keybanc | Overweight | Overweight | Maintain | May 7, 2026 |
| UBS | Neutral | Neutral | Maintain | May 4, 2026 |
| Argus Research | Buy | Buy | Maintain | Aug 26, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Aug 22, 2025 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Aug 15, 2025 |
| Wedbush | Outperform | Outperform | Maintain | Feb 14, 2025 |
| Baird | Outperform | Neutral | Upgrade | Jan 17, 2025 |
| B of A Securities | Buy | Neutral | Upgrade | Jan 16, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Apr 12, 2023 |
| Deutsche Bank | Buy | Buy | Maintain | Jul 13, 2022 |
| SMBC Nikko | Neutral | Outperform | Downgrade | Nov 22, 2021 |
| Stifel Nicolaus | Hold | Buy | Downgrade | Oct 30, 2019 |
| Stifel | Hold | Buy | Downgrade | Oct 30, 2019 |
| Capital One Financial | Equal Weight | Overweight | Downgrade | Oct 28, 2019 |
| Capital One | Equal Weight | Overweight | Downgrade | Oct 28, 2019 |
| Bank of America | Neutral | Neutral | Maintain | Jul 10, 2018 |
| Goldman Sachs | Sell | Neutral | Downgrade | Mar 15, 2017 |
| Hilliard Lyons | Neutral | Underperform | Upgrade | Nov 11, 2016 |
| Macquarie | Neutral | Underperform | Upgrade | Feb 21, 2013 |
| Morgan Keegan | Outperform | Outperform | Maintain | Feb 21, 2012 |
Named analyst price targets
Upside is calculated against the persisted current price $82.04. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Evercore ISI | Analyst unavailable | $100 | $87.22 | +21.9% | Sep 21, 2026 |
| Jefferies | Joe Dickstein | $102 | $89.1 | +24.3% | Sep 15, 2026 |
| Wells Fargo | Analyst unavailable | $104 | $91.18 | +26.8% | Sep 1, 2026 |
| Barclays | Analyst unavailable | $102 | $91.8 | +24.3% | Aug 31, 2026 |
| BMO Capital | Analyst unavailable | $107 | $91.91 | +30.4% | Aug 11, 2026 |
| Cantor Fitzgerald | Richard Anderson | $102 | $92.15 | +24.3% | Jul 31, 2026 |
| Mizuho Securities | Analyst unavailable | $104 | $97.62 | +26.8% | Jul 22, 2026 |
| Barclays | Richard Hightower | $99 | $92.21 | +20.7% | Jul 7, 2026 |
| Scotiabank | Nicholas Yulico | $88 | $81.18 | +7.3% | Jun 18, 2026 |
| Raymond James | Analyst unavailable | $94 | $83.89 | +14.6% | Jun 16, 2026 |
| Deutsche Bank | Omotayo Okusanya | $100 | $83.46 | +21.9% | Jun 16, 2026 |
| Mizuho Securities | Vikram Malhotra | $98 | $88 | +19.5% | May 22, 2026 |
| Scotiabank | Nicholas Yulico | $95 | $88.28 | +15.8% | May 21, 2026 |
| Goldman Sachs | Analyst unavailable | $110 | $88.14 | +34.1% | May 19, 2026 |
| Jefferies | Analyst unavailable | $100 | $88.53 | +21.9% | May 12, 2026 |
| KeyBanc | Analyst unavailable | $95 | $85.34 | +15.8% | May 7, 2026 |
| BMO Capital | Juan Sanabria | $100 | $88.04 | +21.9% | May 4, 2026 |
| RBC Capital | Analyst unavailable | $98 | $88.02 | +19.5% | May 4, 2026 |
| UBS | Analyst unavailable | $93 | $88.02 | +13.4% | May 4, 2026 |
| Evercore ISI | Analyst unavailable | $95 | $87.25 | +15.8% | Apr 29, 2026 |
| Morgan Stanley | Analyst unavailable | $90 | $85.25 | +9.7% | Feb 13, 2026 |
| Argus Research | Analyst unavailable | $88 | $83.38 | +7.3% | Feb 10, 2026 |
| RBC Capital | Analyst unavailable | $91 | $82.79 | +10.9% | Feb 10, 2026 |
| Goldman Sachs | Julien Blouin | $100 | $82.75 | +21.9% | Feb 9, 2026 |
| UBS | Michael Goldsmith | $85 | $83.12 | +3.6% | Feb 9, 2026 |
| Goldman Sachs | Analyst unavailable | $94 | $75.08 | +14.6% | Jan 9, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $93 | $75.4 | +13.4% | Jan 5, 2026 |
| Jefferies | Analyst unavailable | $93 | $78.7 | +13.4% | Dec 15, 2025 |
| KeyBanc | Austin Wurschmidt | $85 | $80 | +3.6% | Dec 4, 2025 |
| Wells Fargo | Analyst unavailable | $88 | $79.76 | +7.3% | Nov 25, 2025 |
| Cantor Fitzgerald | Analyst unavailable | $85 | $73.76 | +3.6% | Oct 31, 2025 |
| Wells Fargo | Analyst unavailable | $80 | $71.5 | -2.5% | Oct 21, 2025 |
| Cantor Fitzgerald | Richard Anderson | $77 | $69.99 | -6.1% | Oct 1, 2025 |
| UBS | Michael Goldsmith | $73 | $67.18 | -11.0% | Sep 19, 2025 |
| Scotiabank | Analyst unavailable | $74 | $67.54 | -9.8% | Aug 28, 2025 |
| Raymond James | Analyst unavailable | $78 | $67.79 | -4.9% | Aug 22, 2025 |
| Argus Research | Analyst unavailable | $75 | $67.87 | -8.6% | Mar 7, 2025 |
| Scotiabank | Analyst unavailable | $72 | $69.18 | -12.2% | Feb 28, 2025 |
| Evercore ISI | James Kammert | $70 | $64.91 | -14.7% | Sep 16, 2024 |
| Wedbush | Richard Anderson | $71 | $64.16 | -13.5% | Sep 10, 2024 |
| Evercore ISI | James Kammert | $64 | $60.28 | -22.0% | Aug 28, 2024 |
| RBC Capital | Michael Carroll | $63 | $59.1 | -23.2% | Aug 9, 2024 |
| Scotiabank | Nicholas Yulico | $59 | $58.56 | -28.1% | Aug 7, 2024 |
| Evercore ISI | James Kammert | $56 | $52.64 | -31.7% | Jul 15, 2024 |
| Morgan Stanley | Ronald Kamdem | $52.5 | $52.69 | -36.0% | Jul 11, 2024 |
| Scotiabank | Nicholas Yulico | $52 | $49.59 | -36.6% | Jun 12, 2024 |
| RBC Capital | Michael Carroll | $52 | $47.14 | -36.6% | May 7, 2024 |
| Evercore ISI | Steve Sakwa | $51 | $47.05 | -37.8% | May 7, 2024 |
| Evercore ISI | Steve Sakwa | $50 | $42.77 | -39.1% | Mar 18, 2024 |
| RBC Capital | Analyst unavailable | $56 | $44.29 | -31.7% | Nov 23, 2022 |
| Morgan Stanley | Analyst unavailable | $54 | $48.26 | -34.2% | Aug 31, 2022 |
| Raymond James | Analyst unavailable | $55 | $47.55 | -33.0% | Aug 31, 2022 |
| Raymond James | Analyst unavailable | $60 | $52.43 | -26.9% | Jul 26, 2022 |
| Morgan Stanley | Analyst unavailable | $52 | $50.74 | -36.6% | Jul 15, 2022 |
| Deutsche Bank | Analyst unavailable | $65 | $50.25 | -20.8% | Jul 13, 2022 |
| Mizuho Securities | Analyst unavailable | $61 | $51.43 | -25.6% | Jul 1, 2022 |
| Morgan Stanley | Analyst unavailable | $59 | $56.74 | -28.1% | Jun 1, 2022 |
| RBC Capital | Analyst unavailable | $63 | $56.09 | -23.2% | May 20, 2022 |
| Deutsche Bank | Derek Johnston | $64 | $51.56 | -22.0% | Feb 17, 2022 |
| Credit Suisse | Omotayo Okusanya | $53 | $52.03 | -35.4% | Feb 1, 2022 |
| Robert W. Baird | Dave Rodgers | $60 | $50.93 | -26.9% | Jan 26, 2022 |
| Citigroup | Nicholas Joseph | $63 | $46.96 | -23.2% | Dec 14, 2021 |
| SMBC Nikko | Richard Anderson | $55 | $49.51 | -33.0% | Nov 22, 2021 |
| Capital One Financial | Daniel Bernstein | $65 | $55.75 | -20.8% | Jun 30, 2021 |
| Scotiabank | Nicholas Yulico | $63 | $55.75 | -23.2% | Jun 30, 2021 |
| KeyBanc | Jordan Sadler | $65 | $56.06 | -20.8% | Jun 29, 2021 |
| Stifel Nicolaus | Steve Manaker | $57 | $56.19 | -30.5% | Jun 28, 2021 |
| Barclays | Steven Valiquette | $67 | $56.27 | -18.3% | Jun 11, 2021 |
Track every rating change on VTR the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationVentas, Inc. is an S&P 500 company enabling exceptional environments that benefit a large and growing aging population. With approximately 1,450 properties in North America and the United Kingdom, Ventas occupies an essential role in the longevity economy. The Company’s growth is fueled by its more than 900 senior housing communities, which provide valuable services to residents and enable them to thrive in supported environments. Ventas aims to deliver outsized performance by leveraging its operational expertise, data-driven insights from its Ventas OITM platform, extensive relationships and strong financial position. The Ventas portfolio also includes outpatient medical buildings, research centers and healthcare facilities. Ventas, Inc. is based in Illinois, Chicago. Ventas, Inc. was incorporated in 1983 in Maryland.
Historical context
All VTR earningsLatest beats and misses
Who reports nextBeat on EPS
Get the VTR recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2026-07-26T00:37:55.686058+00:00
- Polygon adjusted daily market bars · 2026-10-11T02:10:40.036219+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-11T02:10:40.034102+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-11. For educational purposes only; not investment advice.